Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.46 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.45 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8312394 | 0.76 | RAB9A (0.46) | ALDH1A1GAALMNAHPGDSMN1; SMN2 | |
| SCHEMBL7102610 | 0.75 | KEAP1 (0.47) | ADRA2AADRA1APARP14ALDH1A1HPGD | |
| SCHEMBL12768022 | 0.71 | PSIP1 (0.73) | PSIP1PARP14ALDH1A1NR3C1LMNA | |
| SCHEMBL4814588 | 0.71 | NPC1 (0.56) | ADRA2APARP14ALDH1A1GAAHPGD | |
| SCHEMBL9348518 | 0.71 | MAPT (0.62) | PSIP1PARP14BRD4ALDH1A1GAA | |
| SCHEMBL1151568 | 0.71 | ALDH1A1 (0.59) | ALDH1A1GAAHPGD | |
| SCHEMBL4815159 | 0.71 | ALDH1A1 (0.55) | KITFLT1KDRALDH1A1GAA | |
| SCHEMBL7555603 | 0.69 | BRD4 (0.42) | ADRA2AADRA1ABRD4HPGDHTT | |
| SCHEMBL28069822 | 0.68 | STAT3 (0.46) | ALDH1A1GAAHPGD | |
| SCHEMBL7103288 | 0.68 | BRD4 (0.40) | ADRA2APSIP1BRD4LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | ADRA2A 4191/4885PSIP1 3118/4885ADRA1A 4434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.